Spectranetics Completes $2.2 Billion Sale to Royal Phillips

Spectranetics, a U.S.-based vascular intervention device maker, completed a $2.2 billion sale to Royal Philips. Spectranetics' portfolio of devices will aid Philips' strategic expansion into therapy devices. Our firm represented Spectranetics in the sale, applying our deep experience in the medical device industry and specific knowledge of Spectranetics’ strategic goals to allow the company to capitalize on previous acquisitions we had led for it and create a significant value for its shareholders.